Exendin-4 has a C-terminal extension of nine amino acid residues known as the "Trp-cage", which is absent in GLP-1. The "Trp-cage" was believed to interact with nGLP-1R and thereby explain the superior affinity of Exendin-4. However, the molecular details that govern ligand binding and specificity of nGLP-1R remain undefined. Here we report the crystal structure of human nGLP-1R in complex with the antagonist Exendin-4(9-39) solved by the multiwavelength anomalous dispersion method to 2.2 Å resolution. The structure reveals that Exendin-4(9-39) is an amphipathic α-helix forming both hydrophobic and hydrophilic interactions with nGLP-1R. The Trp-cage of Exendin-4 is not involved in binding to nGLP-1R. The hydrophobic bindingsite of nGLP-1R is defined by discontinuous segments including primarily a well-defined α-helix in the Nterminus of nGLP-1R and a loop between two antiparallel ß-strands. The structure provides for the first time detailed molecular insight into ligand binding of the human GLP-1 receptor -an established target for treatment of type 2 diabetes.
G protein-coupled receptors represent the largest protein family encoded by the human genome and they are defined by the presence of seven transmembrane (7TM) helices, an extracellular Nterminus, ligand binding via the extracellular face, an intracellular C-terminus, G protein-coupling and signalling via the intracellular face. Receptors of the B1 subfamily are specifically characterized by three conserved disulfide bonds in the N-terminal extracellular domain (Nt-domain) (1) (2) (3) (4) and by their structurally related peptide hormone ligands, such as glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2), glucagon, glucose-dependent insulinotropic polypeptide (GIP), secretin, vasoactive intestinal polypeptide (VIP), pituitary adenylate cyclase activating polypeptide (PACAP), growth-hormone releasing hormone (GRF), parathyroid hormone (PTH), calcitonin and corticotropin-releasing factor (CRF) (5) . Peptide hormone binding of cloned Family B1 receptors has been investigated for 15 years by pharmacological and biochemical approaches. The current binding model is a two-step mechanism where initially the C-terminal part of the peptide ligand interacts with the Nt-domain of the receptor (6) (7) (8) . In the second step, the N-terminal part of the ligand interacts with the core domain of the receptor (7TM helices and connecting loops), which leads to activation and signal transduction (9) (10) (11) (12) (13) (14) . More recently, it was proposed that the Nt-domain of the secretin receptor was involved in the activation mechanism, but such an endogenous agonist mechanism has not been confirmed for GLP-1R (15) .
The isolated soluble Nt-domains are able to bind their cognate ligands, although the affinity is often reduced compared to the full length receptors (1;3;4;6). The GLP-1R Nt-domain is important for both ligand binding and specificity and it determines almost exclusively the ability of the full length GLP-1R to discriminate between glucagon and GLP-1 (16) . This is physiologically important given the essentially opposite effects of glucagon and GLP-1 on the blood glucose. Detailed structural information exists for ligand-bound forms of the Nt-domain of the mouse CRF receptor 2ß (nCRF-R2ß), the human PACAP receptor (nPAC1) and the human GIP receptor (nGIPR) (17) (18) (19) . The structures confirmed both the existence of a common structural fold and the interaction with the C-terminal part of their cognate ligands. Surprisingly, the binding site and orientation of PACAP was completely different than the bindingsite and orientation of astressin and GIP.
The soluble refolded nGLP-1R binds GLP-1 with lower affinity than the full length GLP-1R in membranes, suggesting that high affinity binding of GLP-1 requires additional interaction with the core domain of GLP-1R (IC 50 of 398 and 1.0 nM, respectively)(6). Specifically, the N-terminal part of GLP-1 is expected to interact with the first extracellular loop (ECL1) and the extracellular end of TM2 of GLP-1R (10;13;14) . Exendin-4 (Ex4) is homologous to GLP-1 and it binds and activates GLP-1R with similar affinity and potency as GLP-1 (20) . In contrast to GLP-1, Ex4 maintains high affinity for nGLP-1R, comparable to that of the full length GLP-1R (1.0 and 1.6 nM, respectively) (6). Ex4 has a C-terminal extension of nine amino acid residues known as the "Trp-cage", which is absent in GLP-1. The NMR structure of Ex4 in aqueous trifluoroethanol (TFE) showed that the Trp-cage folds back onto the central α-helical part of Ex4, forming the smallest known protein-like fold (21;22) . The Trp-cage was suggested to interact with nGLP-1R, thereby explaining the superior affinity of Ex4 compared to GLP-1 (23) . However recent results suggest that the Trp-cage plays only a minor role in receptor binding (24) . Instead the superior affinity of Ex4 was explained concomitantly by its superior α-helical propensity in solution and by superior interactions, due to specific divergent residues in the C-terminal part of GLP-1 and Ex4 (24) . So the role of the Trp-cage in receptor binding is not crystal clear.
Exendin-4(9-39) (Ex4(9-39)) is a competitive antagonist of GLP-1R, displacing both GLP-1 and Ex4 from receptor binding due to its high affinity interaction with nGLP-1R (IC 50 of 0.6 nM) (6;25) . To increase the knowledge about ligand binding of GLP-1R and Family B1 receptors in general, we solved the crystal structure of the complex between nGLP-1R and Ex4(9-39) to 2.1 Å resolution. The structure provides for the first time molecular details of the initial ligand binding step of GLP-1R and it gives a structural explanation of the differential affinity of nGLP-1R towards GLP-1 and Ex4.
Experimental procedures
Protein and Peptide preparation. The nGLP-1R was prepared as earlier described (24) . Briefly, Nterminally 6xHis-tagged nGLP-1R was expressed in E. coli inclusion bodies, isolated as inclusion body protein, solubilised in Gdn-HCl and DTT, dialysed against Gdn-HCl to remove the DTT and refolded using L-Arg and a 1:5 molar ratio of GSH and GSSG. Refolded nGLP-1R was purified by hydrophobic interaction chromatography and size exclusion chromatography. The 6xHis-tag was removed by thrombin cleavage.
Native Ex4(9-39)amide was synthesized as previously described (16) . [SeMet 14, 21 ]-Ex4(9-39)amide was synthesized by incorporation of SeMet residues using the Fmoc strategy on Solid Phase Peptide Synthesis. Fmoc-SeMet-OH was prepared by dissolving L(+)-Selenomethionine (ACROS ORGANICS, New Jersey, USA) in THF/water with 1 equivalent of Na 2 CO 3 and reacting with Fmoc-ONSu. The product was crystallized from Ethyl acetate and n-Heptan as offwhite crystals with a slight odour of selenide.
Purification and crystallization of ligand-bound nGLP-1R. The purified nGLP-1R was concentrated to 1 mg/ml and mixed with 2 fold molar excess of [SeMet 14, 21 ]-Ex4(9-39) or Ex4(9-39). Ligand-bound nGLP-1R was purified by size exclusion chromatography using a Superdex75 column running in 10 mM Tris-HCl pH 7.5 (Supporting information (SI) Figure 1 ). The eluted complex was characterized by SDS-PAGE and Trp fluorescence spectroscopy (data not shown). The complex was concentrated to 7 mg/ml and crystallized by hanging drop vapour diffusion. The crystallization conditions was identified initially using the Crystal Screen and Detergent Screen from Hampton Research and subsequently optimized to 0.1 M Tris-HCl pH 8.5, 0.1 M MgCl 2 , 0.4 M MgTartrate and 9 mM n-Decyl-ß-D-thiomaltoside. Single crystals grew to a size of approximately 0.5x0.1x0.1 µm and they were frozen in liquid N 2 using 25 % glycerol in the cryo solution.
Data collection and structure determination. Diffraction data was collected from a single crystal at three different wavelengths (peak, remote, inflection) at the MAX-lab beamline I911-3 (Lund, Sweden). The data were integrated and scaled using XDS (26) , the crystals belonged to space group P3 1 21 , with the unit cell dimensions a=b=75.9 Å and c=87.8 Å. The two selenium sites of [SeMet 14, 21 ]-Ex4(9-39), the phases and initial electron density map were calculated using autoSHARP (27) . The initial electron density map was of excellent quality and allowed automated building of 65 % of the structural model by ARP/wARP (28) (in the autoSHARP interface) with one complex in the asymmetric unit. The rest of the structural model was build manually without any ambiguity and refined (TLS and restrained) using COOT (29) , REFMAC5 (30) and the CCP4 program suite (31) . The final SeMet-model has 124 residues in allowed and 6 residues in disallowed regions of the Ramachandran plot, a working R-factor of 20.4 % and a free R-factor of 25.0 %. Data collection, phasing and refinement statistics are summarized in Table 1 . Coordinates and structure factors are deposited in the Protein Data Bank under accession code 3C59. Molecular graphics were prepared in PyMOL (DeLano Scientific; www.pymol.org)).
Results and Discussion
Crystallization and structure determination. The nGLP-1R was expressed in E. coli inclusion bodies, refolded and purified as described previously (24) . We synthesised a selenium derivative of the ligand, where Met 14 and Leu 21 were substituted by Selenomethionine (SeMet): [SeMet 14, 21 ]-Ex4(9-39). The solution NMR structure of Ex4 showed previously that Met 14 and Leu 21 were on the same face of the α-helix of Ex4 (22) . In addition, structure/activity studies of GLP-1 showed that these two positions were not important for receptor binding (32) . Indeed [SeMet 14, 21 ]-Ex4(9-39) displaced 125 I-Ex4(9-39) from binding to the refolded nGLP-1R, with the same IC 50 value as native Ex4(9-39) (IC 50 = 5 nM, data not shown). The high affinity interaction allowed co-purification of nGLP-1R and [SeMet 14, 21 ]-Ex4(9-39) by size exclusion chromatography (SI Figure 1) . The intrinsic Trp fluorescence properties of the eluted protein suggested a 1:1 complex (data not shown), where the ligand provided the heavy atoms necessary for the experimental phasing. The complex was crystallized in hanging drops and the structure was solved by the multiwavelength anomalous dispersion (MAD) method to 2.2 Å resolution, using the absorption edge of the two Se atoms in [SeMet 14, 21 ]-Ex4(9-39). Subsequently we crystallized and solved the structure of the complex with native Ex4(9-39) to 2.1 Å resolution by molecular replacement, using nGLP-1R from the initial SeMet-structure as the search model (PDB ID 3C5T). The two structures were essentially identical except for Met 14 and Leu 21 of Ex4(9-39). Data collection and refinement statistics are summarized in Table 1 and all the figures illustrate the structure with the native ligand.
The structure of nGLP-1R. The core structure of nGLP-1R is similar to that of nCRF-R2ß, nPAC1 and nGIPR, showing the three conserved disulfide bonds, two regions of antiparallel ß-sheets (ß-strand [1] [2] [3] [4] [5] Figure 1A and 1B) (18;19) . The Nterminus of nGLP-1R contains an α-helix similar to that of nGIPR and the tertiary structure is stabilized by the disulfide bridges and by multiple intramolecular interactions between the secondary structure elements. Figure 3) .
The ligand and its interactions with nGLP-1R.
Ex-4(9-39) is a well defined α-helix from Leu 10* to Asn 28* and the residues that interact with nGLP-1R lie within Glu 15* and Ser 32* ( Figure 1C ) (Throughout the text, ligand residues are designated with * and Ex4 is numbered 1-39). The residues Asp showed only a minor effect on binding to nGLP-1R, suggesting that the most critical interactions lie within Glu 15* and Lys 27* (24). Nevertheless, the structure suggests that the sidechain of Ser 32* could form a hydrogen bond with Glu 68 of nGLP-1R. The C-terminal tail after Ser 32* of receptor-bound Ex4(9-39) probably folds back on the α-helix in a manner similar to the Trp-cage conformation of Ex4 in TFE solution (22) . However the electron density was very weak for the C-terminus of Ex4(9-39) (Gly ), indicating high mobility and we were unable to build a representative structure of this part of the ligand. Accordingly, specific mutations in the C-terminus of Ex4 were necessary to stabilize the Trp-cage in aqueous solution, where it was otherwise only partially populated (21) . Our results suggest that the specific Trp-cage conformation is not stabilized in the receptor-bound state of Ex4 and that Ser and Leu 26* are buried by the hydrophobic interaction with nGLP-1R and they are the residues of the ligand with the lowest B-factors. Phe 22* of Ex4(9-39) is uniquely conserved in the glucagon peptide subfamily (GLP-1, Exendin-4, GLP-2, glucagon and GIP, Figure 2D) Figure 2C ). Trp 39 and Trp 91 are directly at the hydrophobic interface with Ex4(9-39) and clearly protected from solvent exposure by ligand binding. The hydrophobic interaction between nGLP-1R and Ex4(9-39) defines an area of the structure where water molecules are absent, suggesting a strong hydrophobic effect. The hydrophobic effect was also a strong contributor to the interaction between astressin and nCRF-R2ß (18) . Specifically loop 2 of unbound nCRF-R2ß was very flexible and adopted a well defined conformation upon ligand binding (18) . Superposition of the ligand-bound nGLP-1R and unbound nCRF-R2ß suggests that loop 2 of nGLP-1R is pulled towards Ex4(9-39), engaging in the hydrophobic interaction by a similar induced fit mechanism. The conserved Pro 86 of nGLP-1R is probably important for this binding mechanism and for the specific conformation of loop 2. In the complex with Ex4(9-39), the sidechain of Pro 86 fills out a hydrophobic cavity on the backside of the hydrophobic ligand binding site. Specifically Tyr 88 of loop 2 is positioned between Leu 26* of Ex4(9-39) and Pro 86 of nGLP-1R. The conserved proline holds a similar position in ligand-bound nCRF-R2ß and nGIPR. The ligand induced conformational change of loop 2 might alter the fluorescence properties of Trp 87 of nGLP-1R, although it is rather surface exposed also in the ligand-bound conformation shown here. The extent to which Trp 25* of Ex4(9-39) itself changes its fluorescence properties upon receptor binding is difficult to evaluate. However, Trp 25* is on the edge of the hydrophobic interface with nGLP-1R and it is protected from direct surface exposure only if the Trp-cage is populated. Cterminal truncation of Ex4 altered the fluorescence properties of ligand-bound nGLP-1R (24) . It seems that the Trp-cage influences the fluorescence properties of Ex4 itself while bound to nGLP-1R, supporting the hypothesis that the Trp-cage is partially populated in the complex between Ex4(9-39) and nGLP-1R.
Crystal packing. Four Arg residues on the α-helix of nGLP-1R played a major role in crystal packing, forming ionic interactions and hydrogen bonds with a symmetry related receptor molecule. In addition, the N-terminal part of Ex4(9-39) was packing against a symmetry related receptor molecule. We co-purified, crystallized and solved the structure of nGLP-1R bound to Ex4(5-39) by molecular replacement to 2.1 Å resolution, using nGLP-1R from the initial SeMet-structure as the search model (data not shown). The four additional residues at the N-terminus of the ligand, altered the packing and as a result the complex crystallized in space group P2 1 2 1 2 1 , with two complexes in the asymmetric unit. Nevertheless, the overall structure and the ligandreceptor interactions were not influenced by the new crystal packing. ) most likely explain its lower α-helical propensity in solution as described by NMR and CD spectroscopy (22;36) and its lower affinity for nGLP-1R .
In conclusion, the structural characterization of GLP-1 and Ex4 in solution and the receptor-bound crystal structure of Ex4 show that the superior affinity of nGLP-1R for Ex4 is determined concomitantly by superior hydrophilic and hydrophobic interactions and by a superior α-helical propensity of Ex4 in solution, thus lowering the entropic cost of receptor binding, compared to GLP-1. This explanation also accounts for the ability of Ex4(9-39) to maintain high affinity for GLP-1R in contrast to N-terminally truncated GLP-1 analogs, i.e. Ex4(9-39) is a potent antagonist and GLP-1(9-36) is not (37) .
The glucagon receptor branch. The GLP-1R, GLP-2R, GluR and GIP-R define the glucagon receptor branch within Family B1. The crystal structures of ligand-bound nGLP-1R and nGIPR are very similar (Rmsd = 0.84 Å for Cα atoms of 92 aligned residues of the receptors alone) and the hydrophobic interaction involves conserved residues of both the ligands and the receptors (17 Within the glucagon receptor branch, divergent residues determine specificity for the ligands. The ligand specificity of GLP-1R was shifted 50 fold in favour of glucagon by substitution of the residues Thr 29 -Leu 32 with the corresponding residues of the glucagon receptor (38) . The ability of the Thr * of GLP-1) could define the boundary between residues that interact with the core domain of GLP-1R and residues that interact with nGLP-1R as previously suggested (24) . The α-helices of nGLP-1R and Ex4 are running in the same direction suggesting that both the N-terminals approach the core domain of GLP-1R. Dualcrosslinking of the secretin N-terminus to the secretin receptor also seems to agree with a model where the N-terminus of both the ligand and the receptor are in proximity with the core domain of the receptor (39) . Intriguingly the superior affinity of Ex4 for nGLP-1R is not translated into a superior affinity, potency or efficacy at the full length GLP-1R, compared to GLP-1. Clearly, ligand binding of GLP-1R is more complex than that of the isolated nGLP-1R and the second binding event of GLP-1R somehow compensates for the low affinity of nGLP-1R for GLP-1 relative to Ex4. One of the major differences between the ligandbound structures of Family B1 receptor Nt-domains is the binding site and orientation of the ligand (17) (18) (19) . The binding site of astressin, GIP and Ex4(9-39) is on the same surface of the Nt-domain and the ligand orientation is the same (Figure 4) . However, the position of Ex4(9-39) and GIP is shifted relative to astressin, because they interact with the α-helix of their receptor. Surprisingly, PACAP binds to a completely different site of nPAC1 and has its termini upside-down compared to the other ligands. The N-terminus of Ex4, GIP, CRF and PACAP is important for receptor activation and it is expected to interact with the receptor core domain. In order to accommodate this interaction, the orientation of nPAC1 relative to the receptor core domain (and membrane surface) must be rather different than the orientation of nGLP-1R, nGIPR and nCRF-R2B.
The crystal structure reported here provides detailed molecular information about the first step of peptide ligand binding of the human GLP-1 receptor. It strongly supports the structure based drug design for treatment of type 2 diabetes targeting the GLP-1 receptor. Structural characterization of the full length receptor is necessary to determine the orientation of the Ntdomains, the intimacy of receptor sub-domains and ultimately understand the activation mechanism. Values in parentheses are for the highest-resolution shell. Phasing statistics were extracted from the autoSHARP logfiles. 
